Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsEmblemHealth Formulary Coverage & Prior Auth | Ope…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentEmblemHealthPolicy N/A

    2026 Formulary (List of Covered Drugs)

    Customize your policy alerts

    Sign up for all EmblemHealth policy alerts

    Know when EmblemHealth releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document is EmblemHealth's 2026 formulary listing covered prescription and OTC drugs, formulary rules (e.g., prior authorization, quantity limits, step therapy), and plan contact information; it affects EmblemHealth members and their prescribing providers.

    Policy Summary
    PayerEmblemHealth
    Policy2026 Formulary (List of Covered Drugs)
    Policy CodePolicy N/A
    Change TypeMinor / informational
    Effective DateApr 1, 2026
    Last ReviewApr 1, 2026
    Next Review DateApr 1, 2026
    Key ActionObtain prior authorization when a drug is marked 'PA' before submitting claims to avoid denial.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2026-04-01formulary effective/updated date
    Home deliveryhome delivery available
    PA/QL/ST/LA/SPutilization management tools described
    20+distinct drug entries in this window
    manyentries include Requirements/Limits flags

    Coverage Criteria and Formulary Flags

    General Coverage Conditions

    Coverage and utilization management indicators

    Formulary coverage prerequisites: Drug coverage depends on plan-specific rules such as prior authorization (PA), quantity limits (QL), step therapy (ST), limited availability (LA), and specialty designation (SP).

    Providers must follow plan-specific PA/QL/ST rules where indicated next to drug listings.

    Formulary coverage with product-specific requirements

    Coverage and restrictions for listed drugs are indicated by inline flags

    Formulary listing with specific restrictions: Drugs listed include a drug tier (mostly Tier 1) and may include Requirements/Limits flags: PA (prior authorization), QL (quantity limits), SP (specialty), LA (limited access), ACA, or OTC; coverage is subject to those requirements.

    See per-product Requirements/Limits entries for exact flags and quantity thresholds.

    Policy Summary
    PayerEmblemHealth
    Policy2026 Formulary (List of Covered Drugs)
    Policy CodePolicy N/A
    Change TypeMinor / informational
    Effective DateApr 1, 2026
    Last ReviewApr 1, 2026
    Next Review DateApr 1, 2026
    Key ActionObtain prior authorization when a drug is marked 'PA' before submitting claims to avoid denial.
    SourceLink
    On This Page
    Coverage Criteria and Formulary FlagsSample Drug/Coding Entries and Quantity ExamplesActions, Authorization & Documentation RequiredQuantity Limit Examples by ProductSpecialty, Infusion, and Dispensing ChannelsAbbreviations and Formulary FlagsStep Therapy Indicators and Affected ProductsFormulary Background and ScopePolicy Dates & Revision Notes

    Covered with utilization management controls

    Coverage and utilization management requirements are indicated per-drug in the Requirements/Limits field; drugs are covered subject to these utilization controls when specified.

    Formulary coverage with conditions: Drugs listed are covered on the formulary with the specified Requirements/Limits (PA, SP, LA, QL, ST) where indicated.

    Providers must obtain required PA or use specialty pharmacy as specified; follow QL and ST rules per listing.

    Formulary coverage contingent on Requirements/Limits

    Coverage list entries with requirements/limits

    Formulary coverage entries: Each listed drug line indicates Drug Tier and Requirements/Limits. Coverage is contingent on adherence to any specified Requirements/Limits (PA, QL, LA, SP).

    This is a formulary listing; clinical indications and diagnosis codes are not provided here — follow the per-product Requirements/Limits for authorization and quantity thresholds.

    Formulary coverage with per-product limits

    Coverage and limits for listed psychotropic agents when dispensed within formulary rules

    Formulary coverage with limits: Drugs listed are covered on Drug Tier = 1 when dispensed within the specified Requirements/Limits (quantity limits or other flags).see per-drug QL entries

    Many entries include QL (quantity limits), PA (prior authorization), ST (step therapy), SP (specialty) or LA/ACA flags — consult the specific line item for exact QL values.

    General coverage conditions

    Coverage is subject to product-specific requirements noted (PA, QL, LA, SP, ST).

    Coverage conditions: Drug coverage requires adherence to listed program requirements: obtain PA when PA is indicated; do not exceed QL; use specialty pharmacy when SP is indicated; follow LA or ST restrictions where noted.

    Applied per-product as listed; failure to meet Requirements/Limits may result in denial of coverage at adjudication.

    Please consult the member's Certificate of Coverage and benefits summary before assuming coverage. Not all drugs in this formulary are paid for by all drug benefit plans; coverage may vary by plan and by member. The Certificate of Coverage (and the member ID card phone number) identifies plan-specific copays, restrictions and any additional requirements that may apply to a given prescription.

    This extract does not contain standalone clinical medical‑necessity decision trees or broad exclusion rules. Instead, coverage conditions are shown at the product level using inline requirement flags such as PA (prior authorization), QL (quantity limit), ST (step therapy), LA (limited access) and SP (specialty). Providers should follow those product-level Requirements/Limits and submit supporting documentation as required when requesting coverage.

    Some insulin products in the listing are designated OTC (over‑the‑counter). For example, HUMULIN R and certain NOVOLIN R presentations are marked OTC in the formulary and also list associated quantity limits. OTC designation may alter coverage or member cost‑sharing; verify benefit plan treatment of OTC insulins for each member.

    No blanket exclusions are provided in these document segments. Individual formulary line items show coverage status and, where applicable, per‑product limitations (for example, quantity limits, PA, LA, SP). Coverage for each listed product is therefore contingent on meeting any Requirements/Limits shown for that product.

    There are no explicit lists of excluded drugs in these excerpts. Drugs that are listed without a Requirements/Limits flag should be treated under the plan's standard coverage rules, while those with flags (e.g., PA/QL/LA/SP) require adherence to the specified administrative controls before the plan will pay.

    These chunks do not state specific formulary exclusions. Absence of an exclusion statement here does not imply universal coverage; coverage remains subject to the product‑level Requirements/Limits and the member’s Certificate of Coverage.

    No explicit exclusions are listed in this portion of the formulary. Products shown include their Requirements/Limits (for example, INGREZZA lists LA, PA, QL and SP), which govern coverage and any additional administrative steps required.

    Within these excerpts there are no statements declaring items as not medically necessary. Drug listings are informational and indicate coverage status and Requirements/Limits; clinical determinations about medical necessity would be reached through the plan’s prior authorization or appeals processes when applicable.

    No products are explicitly labeled 'not medically necessary' in the provided segments. Coverage determinations that a therapy is not medically necessary would be made through the plan’s review procedures and are not described in these chunks.

    The supplied excerpts do not include any explicit 'not medically necessary' policy language. If a prescriber believes a product is medically necessary despite Requirements/Limits, submit a prior authorization request with clinical justification per the plan’s PA process.

    Sample Drug/Coding Entries and Quantity Examples

    Sample Covered Drugs (antibiotics)mixedCovered
    amoxicillin (trihydrate) chew tab 125 mg, 250 mgAMOXICILLIN - listed, Drug Tier = 1
    amoxicillin (trihydrate) cap 250 mg, 500 mgamoxicillin caps, Drug Tier = 1
    amoxicillin (trihydrate) for susp 125 mg/5ml, 200 mg/5ml, 250 mg/5ml, 400 mg/5mlamoxicillin suspensions, Drug Tier = 1
    amoxicillin (trihydrate) tab 500 mg, 875 mgamoxicillin tablets, Drug Tier = 1
    amoxicillin & k clavulanate for susp 200-28.5 mg/5ml, 250-62.5 mg/5ml, 400-57 mg/5mlamoxicillin/clavulanate suspensions, Drug Tier = 1
    amoxicillin & k clavulanate for susp 600-42.9 mg/5ml (Augmentin es-600)amoxicillin/clavulanate susp (ES-600), Drug Tier = 1
    amoxicillin & k clavulanate for susp 125-31.25 mg/5mlAUGMENTIN - amoxicillin & k clavulanate for susp 125-31.25 mg/5ml, Drug Tier = 1
    amoxicillin & k clavulanate tab er 12hr 1000-62.5 mgamoxicillin/clavulanate extended release, Drug Tier = 1
    amoxicillin & k clavulanate tab 250-125 mg, 500-125 mg, 875-125 mgamoxicillin/clavulanate tablets, Drug Tier = 1
    cefadroxil tab 1 gmCEFADROXIL - Drug Tier = 1
    1–10 of 21
    1/3
    Antibacterials / Tetracyclinesmixed
    fidaxomicin tab 200 mgDificid — listed with Requirements/Limits
    demeclocycline hcl tab 150 mg, 300 mgDemeclocycline — Drug Tier = 1
    doxycycline hyclate cap 50 mg, 100 mg; doxycycline hyclate tab 20 mg, 100 mgDoxycycline formulations — Drug Tier = 1
    NUZYRA - omadacycline tosylate tab 150 mgOmadacycline (Nuzyra), Drug Tier = 1; Requirements/Limits = LA
    Fluoroquinolones / Aminoglycosidesmixed
    delafloxacin meglumine tab 450 mgBAXDELA — Drug Tier = 1
    ciprofloxacin for oral susp 250 mg/5ml; ciprofloxacin hcl tab 250 mg, 500 mg, 750 mgCIPRO — various oral forms, Drug Tier = 1
    levofloxacin oral soln 25 mg/ml; levofloxacin tab 250 mg, 500 mg, 750 mgLevofloxacin formulations, Drug Tier = 1
    ARIKAYCE - amikacin sulfate liposome inhal susp 590 mg/8.4mlARIKAYCE — Requirements/Limits = LA, PA, QL (28 vials/28 days), SP
    Antimycobacterial agentsmixed
    ethambutol hcl tab 100 mg, 400 mgEthambutol — Drug Tier = 1
    isoniazid syrup 50 mg/5ml; isoniazid tab 100 mg, 300 mgIsoniazid formulations — Drug Tier = 1
    SIRTURO - bedaquiline fumarate tab 20 mg, 100 mgBedaquiline (SIRTURO) — Requirements/Limits = LA, SP
    Antifungalsmixed
    CRESEMBA - isavuconazonium sulfate cap 74.5 mg, 186 mgIsavuconazonium (CRESEMBA) — Requirements/Limits = PA
    itraconazole cap 100 mg; itraconazole oral soln 10 mg/mlItraconazole (Sporanox) — Requirements/Limits = QL (120 capsules/30 days)
    NOXAFIL - posaconazole for delayed release susp packet 300 mg; posaconazole susp 40 mg/ml; posaconazole tab delayed release 100 mgPosaconazole (NOXAFIL) — Requirements/Limits = PA
    Antivirals / HIV / HCV therapiesmixed
    acyclovir (caps, susp, tabs)Acyclovir formulations — Drug Tier = 1
    APRETUDE - cabotegravir im extended release 600 mg/3mlAPRETUDE — Requirements/Limits = ACA, LA, SP
    BIKTARVY - bictegravir-emtricitabine-tenofovir afBIKTARVY — Requirements/Limits = QL (30 tablets/30 days)
    EPCLUSA - sofosbuvir-velpatasvir pellet pack/tabEPCLUSA — Requirements/Limits = PA, QL (28 packets/28 days or 28 tablets/28 days), SP
    HARVONI - ledipasvir-sofosbuvir pellet pack/tabHARVONI — Requirements/Limits = PA, QL (28 packets/28 days or 28 tablets/28 days), SP
    MAVYRET - glecaprevir-pibrentasvir tab/pellet packMAVYRET — Requirements/Limits = PA, QL (84 tablets/28 days or 140 packets/28 days), SP
    Additional antivirals and specialty agentsmixed
    PEGASYS - peginterferon alfa-2a prefilled syr/ injPEGASYS — Requirements/Limits = PA, SP
    PREVYMIS - letermovir tab/pellet packPREVYMIS — Requirements/Limits = QL (200 tablets/365 days or 800 packets/365 days)
    SUNLENCA - lenacapavir sodium (therapy pack 5 x 300 mg; tab 300 mg)SUNLENCA — Requirements/Limits = LA, QL (5 tablets/365 days for therapy pack; 4 tablets/365 days for tab), SP
    valacyclovir hcl tab 500 mg, 1 gm (Valtrex)Valacyclovir — Drug Tier = 1
    Selected drug line-itemsmixed
    SUNLENCA - lenacapavir sodium tab therapy pack 5 x 300 mgSUNLENCA therapy pack — Requirements/Limits = LA, QL (5 tablets/365 days), SP
    SUNLENCA - lenacapavir sodium tab 300 mgSUNLENCA tab — Requirements/Limits = LA, QL (4 tablets/365 days), SP
    SYMTUZA - darunavir-cobic-emtricitab-tenofov af tab 800-150-200-10 mgSYMTUZA — Requirements/Limits = QL (30 tablets/30 days)
    Selected drug line-itemsmixed
    YEZTUGO - lenacapavir sodium subcutaneous soln 463.5 mg/1.5mlYEZTUGO — Requirements/Limits = ACA, SP
    YEZTUGO - lenacapavir sodium tab 300 mgYEZTUGO tab — Requirements/Limits = ACA, QL (4 tablets/365 days), SP
    XOFLUZA - baloxavir marboxil tab therapy pack 1 x 40 mg, 1 x 80 mgXOFLUZA — Requirements/Limits = QL (2 tablets/120 days)
    Select agents with PA/QLmixed
    linezolid for susp 100 mg/5ml (Zyvox)Linezolid suspension — Requirements/Limits = PA
    nitazoxanide tab 500 mgNitazoxanide — Requirements/Limits = QL (12 tablets/90 days)
    NDC/CPT/HCPCS codes not provided in this excerptmixed
    No codes listed
    Formulary drug entries (selected examples)mixed
    TIROSINTlevothyroxine sodium cap and solution strengths listed
    ACTHARcorticotropin inj gel 80 unit/ml
    GENOTROPINsomatropin for subcutaneous inj cartridge
    GALAFOLDmigalastat hcl cap 123 mg
    IMCIVREEsetmelanotide acetate subcutaneous soln 10 mg/ml
    JYNARQUEtolvaptan tablets (various pack sizes)
    PALYNZIQpegvaliase-pqpz subcutaneous solution
    STRENSIQasfotase alfa subcutaneous inj
    TYMLOSabaloparatide subcutaneous solution pen
    DIGOXINdigoxin oral solution and tablets
    1–10 of 12
    1/2
    NDC/HCPCS/CPT not listed in this segmentmixed
    No codes listed
    Sample listed oral and injectable drugs from segmentmixed
    alosetron hcl tab 0.5 mg / 1 mgLotronex — listed
    AURYXIA - ferric citrate tab 1 gmAURYXIA — Requirements/Limits = QL (360 tablets/30 days)
    BYLVAY - odevixibat cap 400 mcg, 1200 mcgBYLVAY — Requirements/Limits = LA, PA, SP
    CIMZIA - certolizumab pegol 200 mg/mlCIMZIA — Requirements/Limits = PA, QL (4 syringes/28 days), SP
    Biologic injectablesmixed
    OMVOH mirikizumab-mrkzOMVOH — multiple presentations; Requirements/Limits = LA, PA, QL, SP
    SKYRIZI risankizumab-rzaaSKYRIZI — Requirements/Limits = PA, QL (1 pen/56 days), SP
    Specialty biologics and advanced therapiesmixed
    VOWST fecal microbiota spores, live-brpk capsVOWST — Requirements/Limits = LA, PA, QL (12 capsules/365 days), SP
    ZYMFENTRA infliximab-dyybZYMFENTRA — Requirements/Limits = LA, PA, QL (2 pens/28 days), SP
    Formulary drug items (partial)NDC/molecular
    Wellbutrin xl 300 mgbupropion hcl tab er 24hr 300 mg — Requirements/Limits = QL (30 tablets/30 days)
    bupropion 75 mgbupropion hcl tab 75 mg — Requirements/Limits = QL (180 tablets/30 days)
    bupropion 100 mgbupropion hcl tab 100 mg — Requirements/Limits = QL (120 tablets/30 days)
    Celexa 10 mgcitalopram hydrobromide tab 10 mg — Requirements/Limits = QL (120 tablets/30 days)
    Specialty / limited quantity drugsmixed
    ZURZUVAE 20/25 mgzuranolone cap 20 mg, 25 mg — Requirements/Limits = QL (28 capsules/365 days), SP
    ZURZUVAE 30 mgzuranolone cap 30 mg — Requirements/Limits = QL (14 capsules/365 days), SP
    Hetlioztasimelteon capsule 20 mg (Hetlioz) — Requirements/Limits = PA, QL (30 capsules/30 days), SP
    Sample listed products (partial)mixed
    phenobarbital elixir 20 mg/5mlphenobarbital elixir — Drug Tier = 1
    ramelteon 8 mgramelteon tab 8 mg (Rozerem) — Requirements/Limits = QL (30 tablets/30 days)
    tasimelteon 20 mgtasimelteon capsule 20 mg (Hetlioz) — Requirements/Limits = PA, QL (30 capsules/30 days), SP
    ADHD/narcolepsy/anorexiants group examplesmixed
    Adderall XRamphetamine-dextroamphetamine cap er 24hr various strengths — Requirements/Limits = QL as listed
    Nuvigilarmodafinil tab various strengths
    atomoxetineatomoxetine hcl caps various strengths — Requirements/Limits = QL as listed
    Selected neurology/sleep productsmixed
    SUNOSIsolriamfetol hcl tab 75 mg, 150 mg — Requirements/Limits = PA, QL (30 tablets/30 days)
    WAKIXpitolisant hcl tab 4.45 mg, 17.8 mg — Requirements/Limits = LA, PA, QL (60 tablets/30 days), SP
    XYWAVcalcium/mag/potassium/sodium oxybates oral soln 500 mg/ml — Requirements/Limits = LA, PA, QL (540 mls/30 days), SP
    Drug list (no billing codes provided)mixed
    NDC/HCPCS not listedNo explicit procedure or NDC/HCPCS codes are provided in this section; entries are drug name, strength, tier, and Requirements/Limits.
    Quantity limits (examples)
    ARIKAYCE (amikacin liposome inhalation)Quantity limit: 28 vials per 28 days (QL 28 vials/28 days).
    EPCLUSA (sofosbuvir-velpatasvir)Quantity limit: 28 packets or 28 tablets per 28 days (PA, QL 28 packets/28 days or QL 28 tablets/28 days).
    MAVYRET (glecaprevir-pibrentasvir)Quantity limit: 84 tablets per 28 days (QL 84 tablets/28 days).
    XOFLUZA (baloxavir marboxil)Therapy pack (1 x 40 mg, 1 x 80 mg) — Quantity limit: 2 tablets per 120 days (QL 2 tablets/120 days).
    Nitazoxanide tab 500 mgQuantity limit: 12 tablets per 90 days (QL 12 tablets/90 days).
    Quantity limit examples
    GALAFOLD (migalastat)Quantity limit: 14 capsules per 28 days (QL 14 capsules/28 days).
    IMCIVREE (setmelanotide)Quantity limit: 10 vials per 30 days (QL 10 vials/30 days).
    Selected injectables (example)Example quantity/pack limits: 1 pen per 28–30 days for some prefills (QL as specified per product).
    Quantity limits examples
    Propranolol oral solution 20 mg/5 mlQuantity limit: 4800 mls per 30 days (QL 4800 mls/30 days).
    Nimodipine oral solution 60 mg/20 ml (3 mg/ml)Quantity limit: 2520 mls per 21 days (QL 2520 mls/21 days).
    NYMALIZE - nimodipine oral solution 6 mg/mlQuantity limit: 1260 mls per 21 days (QL 1260 mls/21 days).
    Quantity limits examples
    VASCEPA (icosapent ethyl) 0.5 gQuantity limit: 240 capsules per 30 days (QL 240 capsules/30 days).
    VASCEPA (icosapent ethyl) 1 gQuantity limit: 120 capsules per 30 days (QL 120 capsules/30 days).
    Common tablet limits (examples)Examples include 30, 60, or 90 tablets per 30 days depending on product/strength (QL as specified).
    Examples of Quantity Limits
    Inhaler limits (examples)Examples: QL 1 inhaler/30 days and QL 3 inhalers/30 days depending on product (e.g., STIOLTO RESPIMAT QL 1 inhaler/30 days; SYMBICORT QL 3 inhalers/30 days).
    Packet/blister pack limitsExample: TRIKAFTA QL 56 packets/28 days (or QL 90 tablets/30 days for some presentations).
    Capsule/tablet examplesExamples include QL 60 capsules/30 days for some products; follow per-product QL listing (highlighted where applicable).
    Quantity Limits (examples)
    INGREZZA (valbenazine) therapy packQuantity limit: QL 28 capsules/180 days for therapy pack or QL 30 capsules/30 days for single-strength listings (LA, PA, SP as specified).
    Sodium oxybate (Xyrem) / XYWAVQuantity limit: QL 540 mls per 30 days (sodium oxybate/XYWAV QL 540 mls/30 days; LA, PA, SP).
    VUMERITY (diroximel fumarate)Quantity limit: QL 120 capsules per 30 days (QL 120 capsules/30 days).
    Common quantity limits
    Common tablet QL examplesCommon quantity limits shown: 30 tablets/30 days and 60 tablets/30 days for many oral products (e.g., bupropion ER QL 30 tablets/30 days).
    Capsules per year examplesExamples include 28 capsules/365 days and 14 capsules/365 days for select specialty oral products (e.g., zuranolone listings).
    Psychotropic limits (example)Brexpiprazole QL 30 tablets/30 days; risperidone ODT QL 60 tablets/30 days — follow product-specific QL.
    Quantity Limits examples
    Typical short-term QL exampleExamples include QL 30 tablets/30 days for many chronic oral medications and QL 540 mls/30 days for certain oral solutions (e.g., sodium oxybate).
    Sodium oxybate (Xyrem)Quantity limit reaffirmed: QL 540 mls per 30 days (LA, PA, SP).
    Product-specific variabilityValues vary by product; always use the per-line Requirements/Limits entry (e.g., VUMERITY QL 120 capsules/30 days).
    Quantity limits (examples)
    Sodium oxybate (Xyrem)Quantity limit: QL 540 mls per 30 days (sodium oxybate/Xyrem).
    VUMERITY (diroximel fumarate)Quantity limit: QL 120 capsules per 30 days (QL 120 capsules/30 days).
    Adalimumab productsQuantity limit example for some biologics: QL 2 syringes/pens per 28 days — check product line for exact QL.

    Actions, Authorization & Documentation Required

    Prior Authorization

    Obtain prior authorization when 'PA' is indicated

    Certain drugs listed with the Requirements/Limits flag 'PA' require prior authorization before the plan will pay; if PA is not obtained, the plan may not cover the drug.

    • Obtain PA prior to dispensing when the drug line shows 'PA' in Requirements/Limits.
    • If PA is not received, coverage may be denied at point of adjudication.
    Prior Authorization

    Request PA for listed antifungals and HCV antivirals

    Prior authorization is specifically noted for selected antifungals (e.g., CRESEMBA, posaconazole, voriconazole) and many hepatitis C direct-acting antivirals (e.g., EPCLUSA, HARVONI, MAVYRET) — providers must request PA as shown next to those products.

    • Follow the Requirements/Limits entry (PA and any accompanying QL or SP) on each antiviral or antifungal line item.
    • Example: EPCLUSA is listed with 'PA, QL (28 packets/28 days), SP' and requires PA before coverage.
    Prior Authorization

    Follow per-product PA and administrative flags (ACA/LA)

    Some products are annotated with PA or other administrative flags (ACA, LA) in the Requirements/Limits column; providers must obtain the specific authorization or satisfy the administrative requirement shown before dispensing.

    • If a product shows 'ACA' or 'LA' in addition to PA, follow the administrative/site instructions and obtain required approvals.
    • Ensure the PA request references the Requirements/Limits shown on the formulary line item.
    Prior Authorization

    Adhere to the requirement type shown for example products (YEZTUGO, SUNLENCA)

    Examples in the formulary show specific drugs with PA/ACA/LA and QL flags (for example, YEZTUGO and SUNLENCA) — follow the exact requirement type listed for each product when requesting coverage.

    • SUNLENCA entries show 'LA, QL (4–5 tablets/365 days), SP' — obtain PA and comply with QL and site/specialty routing.
    • YEZTUGO lines include 'ACA, SP' — follow the listed administrative and specialty requirements.
    Prior Authorization

    Submit PA and use specialty pharmacy when 'SP' is indicated

    Many specialty and oncology agents are managed through specialty pharmacy and require prior authorization; providers must submit PA requests and ensure specialty routing when 'SP' is indicated.

    • Oncology agents frequently list 'LA, PA, QL, SP' — obtain PA and route to specialty pharmacy as required.
    • Quantity limits (QL) shown for specialty agents must be respected when completing PA requests.
    Prior Authorization

    Obtain PA for listed oncology and specialty oral agents

    Numerous specialty oncology and oral targeted agents in the formulary require prior authorization and often include QL and site provisioning (SP/LA); providers must request PA and document adherence to QL and site requirements.

    • Examples: LENVIMA therapy packs list 'LA, PA, QL (30–90 capsules/30 days), SP' — obtain PA and follow QL.
    • Drugs with LA/PA/SP designations require prior approval before coverage is provided.
    Prior Authorization

    Request PA for drugs marked 'PA' in the formulary

    Many formulary line-items include PA or other requirement flags; providers must request prior authorization for drugs marked 'PA' before dispensing to obtain coverage.

    • Where the Requirements/Limits column includes 'PA' (e.g., XTANDI, ACTHAR), submit a PA request per payer instructions.
    • Do not assume coverage without completing the PA process for listed products.
    Prior Authorization

    Obtain PA for GLP‑1/GIP–GLP‑1 and similar agents

    Certain GLP‑1/GIP–GLP‑1 agents and other specialty metabolic products (e.g., MOUNJARO, OZEMPIC, TRULICITY) are listed with PA and QL requirements; obtain PA and document compliance with QL values when submitting claims.

    • MOUNJARO entries show 'PA, QL (4 pens/180 days or 4 pens/28 days depending on strength)' — include this information in the PA request.
    • OZEMPIC and TRULICITY are listed with 'PA, QL' — secure PA prior to dispensing.
    Prior Authorization

    Submit PA for specified agents listed with 'PA'

    Drugs flagged with 'PA' in the Requirements/Limits column (examples include ACTHAR, carglumic acid, GENOTROPIN) require prior authorization; providers must submit PA requests for these specific agents.

    • Refer to the formulary line item for each product and submit PA when 'PA' is shown.
    • Include any product-specific details from the Requirements/Limits field in the authorization request.
    Prior Authorization

    Obtain PA for the listed selected products

    Multiple products (e.g., nimodipine oral solutions, DIURIL suspension, FUROSCIX, NEXLETOL/NEXLIZET, REPATHA, VASCEPA, ENTRESTO, CAMZYOS) are shown with 'PA' in Requirements/Limits — providers must obtain PA for these items as listed.

    • Check the formulary line item for each product's Requirements/Limits and submit PA where indicated.
    • Include quantity justification when QL is present (e.g., REPATHA QL values) in the PA documentation.
    Prior Authorization

    PA required for drugs noted 'PA' (including VASCEPA and biologics)

    Numerous drugs are designated 'PA' in the Requirements/Limits column (examples include VASCEPA, ADEMPAS and many biologics); providers must request prior authorization per the formulary entry before the plan will cover the drug.

    • When a formulary entry shows 'PA' (with or without QL, LA, SP), submit the payer's prior authorization request before dispensing.
    • For biologics noted with PA and SP, ensure PA documentation includes specialty routing information.
    Prior Authorization

    Obtain PA and comply with LA/QL/SP for specialty/high‑cost drugs

    Many specialty or high‑cost medications are listed with PA and may also show LA, QL and SP designations; obtain prior authorization and comply with any limited access or specialty requirements shown to secure coverage.

    • Check for accompanying QL, LA or SP flags and include relevant site-of-care or specialty pharmacy details in the PA submission.
    • Failure to include site or specialty information when required may delay or prevent coverage.
    Prior Authorization

    Request PA and follow listed limits/route per product

    The formulary indicates PA and/or limits (QL, LA, SP, ST) for numerous drugs; providers must submit prior authorization requests and adhere to specified limits and routing per the Requirements/Limits field.

    • Submit PA where 'PA' is listed and ensure quantities requested do not exceed QL values.
    • If 'SP' or 'LA' is present, route dispensing to the specialty pharmacy or designated site of care.
    Prior Authorization

    Obtain PA and follow QL/SP for tasimelteon (Hetlioz)

    Tasimelteon (Hetlioz) is listed with 'PA, QL (30 capsules/30 days), SP' — providers must obtain prior authorization and follow the specialty pharmacy and quantity limit noted on the formulary line.

    • Include the QL (30 capsules/30 days) in the PA request for tasimelteon.
    • Ensure specialty pharmacy routing is used when arranging dispensing.
    Prior Authorization

    Follow QL and specialty routing for zuranolone (ZURZUVAE)

    Zuranolone (ZURZUVAE) entries include QL values and specialty designation (e.g., QL 28 capsules/365 days; QL 14 capsules/365 days) — providers must observe those limits and any specialty routing when seeking coverage.

    • Do not exceed the listed QL per 365‑day period when requesting fills.
    • If SP is indicated, coordinate dispensing via specialty pharmacy as required.
    Prior Authorization

    Request PA for all drugs listed with 'PA'

    Many products across the formulary are indicated as requiring prior authorization; providers must request PA for any drug with 'PA' shown in the Requirements/Limits column before dispensing to avoid non‑coverage.

    • Review the Requirements/Limits field for each line item and submit PA when 'PA' is present.
    • Include product‑specific QL, LA, SP or ST details in the authorization request where shown.
    Prior Authorization

    Submit PA for listed biologic and specialty agents

    Multiple listed products (including many biologic and specialty agents) require prior authorization as indicated in the Requirements/Limits field; providers must submit PA requests and follow specialty routing where 'SP' is shown.

    • Examples include biologics with 'PA' and QL (e.g., adalimumab products showing PA, QL (2 pens/28 days), SP).
    • Ensure PA requests contain documentation to satisfy medical necessity and any site/specialty requirements.
    Step Therapy

    Comply with step therapy requirements when 'ST' is shown

    Step therapy (ST) applies where the formulary marks a drug with 'ST'; providers must follow plan step edits (try required preferred drugs first) or request an exception.

    • If the Requirements/Limits column includes 'ST' for a product, ensure the member has completed required prior steps or submit a step‑therapy exception request.
    • Examples: agents annotated with 'ST' (e.g., FOSRENOL, VELPHORO, SAVELLA) are subject to step therapy where indicated.
    Note

    Follow utilization management and site/administrative flags (SP/LA/ACA)

    Some products include 'SP' and 'LA' or 'ACA' flags that imply utilization management or site/administrative rules; when these flags appear, providers must follow plan‑specific step, site or administrative processes before dispensing.

    • 'SP' typically indicates specialty pharmacy routing — arrange specialty dispensing when shown.
    • 'LA' or 'ACA' flags may require site‑of‑care approval or administrative coverage steps prior to approval.
    Documentation Required

    Check Requirements/Limits flags on each formulary line

    The formulary places initials after drug names (PA, QL, ST, LA, SP) to indicate required actions — providers must consult the Requirements/Limits field on each line and follow the plan's instructions when prescribing or submitting claims.

    • Confirm whether PA, QL, ST, LA or SP applies from the line item before submitting a claim.
    • Use the Requirements/Limits details to populate PA requests and support documentation.
    Documentation Required

    Document compliance with Requirements/Limits on claims

    Pharmacy claims should document compliance with the Requirements/Limits field (for example, QL values and PA where indicated) to support coverage — include quantity justification and PA documentation where required.

    • When a QL is present, include quantity justification in the claim or PA submission.
    • Attach prior authorization approval codes or supporting medical documentation to the claim when 'PA' is required.
    Denial Risk

    Follow PA and QL processes to avoid denials

    Prescribers and pharmacies must follow the plan's PA and QL processes where indicated; failure to obtain required PA or to adhere to QL may result in denial of coverage at claim adjudication.

    • Submit PA requests per payer procedures and ensure requested quantities do not exceed QL.
    • If authorization is not obtained or QL exceeded, the claim may be denied.
    Billing Rule

    Ensure claims reference exact quantity limits and PA

    Pharmacy claims must meet specified Requirements/Limits (e.g., PA and QL such as 60 tablets/30 days for enzalutamide or 30 tablets/30 days for niraparib) — providers should ensure claims and PA submissions reference the exact QL values.

    • Include the formulary QL value in the PA or claim to avoid dose/quantity denials.
    • Examples: XTANDI = QL (60 tablets/30 days); ZEJULA = QL (30 tablets/30 days).
    Denial Risk

    Risk of denial if PA not obtained

    Failure to obtain required prior authorization may result in the plan not covering the drug; providers should request PA in advance and submit supporting documentation to mitigate denial risk.

    • Obtain PA prior to dispensing when 'PA' is indicated; if not obtained, coverage may be denied.
    • Providers may request exceptions per plan processes, but coverage is not guaranteed without PA.
    Documentation Required

    Heed PA/LA/SP/ACA flags as triggers for administrative controls

    Drugs flagged with 'PA', 'LA', 'SP' or 'ACA' indicate administrative controls that may trigger prior authorization or special handling; providers must follow those controls to obtain coverage.

    • When these flags appear in Requirements/Limits, include evidence of meeting those controls in the authorization submission.
    • Specialty or limited‑access products often require additional documentation or site approvals.
    Denial Risk

    Denial risk when exceeding QL or missing required authorizations

    Requests that exceed listed quantity limits (QL) or lack required PA/LA/SP authorizations may be denied or subjected to additional review at adjudication.

    • If a request exceeds the QL shown on the formulary line, obtain PA or provide justification to avoid denial.
    • Ensure site‑of‑care approvals are in place for LA/FF/ SP‑designated products.
    Note

    Coordinate specialty pharmacy routing and PA when 'SP' is listed

    If specialty pharmacy (SP) requirements are present for a drug, providers must arrange dispensing through the specialty channel and obtain any required PA; failure to do so may limit or deny coverage.

    • Coordinate with the plan's specialty pharmacy when 'SP' is indicated on the drug line.
    • Include specialty routing information and PA documentation with the claim.
    Denial Risk

    Obtain PA and adhere to QL to prevent claim denial

    Claims for drugs listed with 'PA' or that exceed specified QL values may be denied if authorization is not obtained; providers should secure PA and respect QL to prevent claim denials.

    • For drugs with PA and QL, include PA approval and ensure dispensed quantities align with QL before submitting the claim.
    • Examples: sodium oxybate (Xyrem) shows 'LA, PA, QL (540 mls/30 days), SP' — obtain PA and follow QL.
    Note
    Note

    Quantity Limit Examples by Product

    Definitions and formulary flags
    Generic drugsLower-cost versions of brand-name drugs; pharmacists will generally dispense generics when available
    Formulary abbreviationsPA = Prior Authorization; QL = Quantity Limit; ST = Step Therapy; LA = Limited Access; SP = Specialty; OTC = Over the Counter
    SPSpecialty pharmacy requirement — payer-managed distribution

    Specialty, Infusion, and Dispensing Channels

    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Abbreviations and Formulary Flags

    Step Therapy Indicators and Affected Products

    Policy pointDetails / examples
    Step therapy (ST) requirement
    Step Therapy (ST) may require trying specified preferred drugs first; exceptions can be requested. (See formulary abbreviations and step therapy description).
    Policy pointDetails / examples
    Administrative / specialty flags on HIV and specialty agents
    Certain specialty HIV agents and other specialty products are flagged with administrative/limited-access indicators (LA, ACA) and specialty designation (SP) — e.g., SUNLENCA listings with LA, QL and SP; PALFORZIA entries with LA, SP.
    Policy pointDetails / examples
    Prior authorization and specialty pharmacy handling
    Many specialty and oncology agents require prior authorization (PA) and are managed through specialty pharmacy (SP); examples include oncology biologics and other specialty products listed with PA and SP flags.
    Policy pointDetails / examples
    Complete required prior steps per plan
    Presence of LA/FF flags suggests additional step or formulary restrictions; providers should complete any required prior steps per the plan before coverage. (Examples: leucovorin with FF/PA/QL; various therapy packs showing LA/PA/QL).
    Policy pointDetails / examples
    Contraceptives and specialty agents with administrative flags
    Some contraceptives and specialty agents are flagged with ACA or LA (administrative coverage annotations) or PA, which may imply administrative or step-related requirements; specific step sequences are not provided in this extract (examples: many contraceptives listed with ACA; IUDs KYLEENA noted ACA, LA).
    Policy pointDetails / examples
    PA required for GLP‑1 / related agents
    Prior authorization (PA) is required before coverage for several GLP‑1 and related agents — e.g., MOUNJARO and OZEMPIC are listed with PA and quantity limits.
    Policy pointDetails / examples
    Agents designated 'ST' / step therapy noted in Requirements/Limits
    Some drugs are designated 'ST' or have step therapy indicated in Requirements/Limits; follow the plan's step therapy rules where ST appears (examples: FANAPT entries show ST; other lines list ST alongside QL).
    Policy pointDetails / examples
    No explicit step-therapy steps listed in extract
    The document does not provide step-by-step ST sequences in this extract; some agents are marked ACA indicating administrative coverage controls rather than explicit step edits. Providers should refer to plan systems for specific step requirements.
    Policy pointDetails / examples
    No explicit ST sequences provided
    No explicit step-therapy sequences are provided in these chunks; the listings show PA/QL/LA/SP designations but not the detailed step order.
    Policy pointDetails / examples
    ST applies where 'ST' appears in Requirements/Limits
    Step therapy applies to drugs with 'ST' in the Requirements/Limits field — examples in the formulary include FOSRENOL / VELPHORO entries and other listed agents with ST.
    Policy pointDetails / examples
    Products annotated 'ST' alongside QL entries
    Several listed products include 'ST' indicating they are subject to step therapy — examples include titration packs and formulations (e.g., FETZIMA/FANAPT titration packs referenced with QL and ST in the listings).
    Policy pointDetails / examples
    SAVELLA marked ST
    SAVELLA (milnacipran) is specifically listed with ST (and QL), indicating step therapy applies to this product.
    Policy pointDetails / examples
    Selected medications noted as subject to step therapy
    Multiple medications are noted as subject to step therapy where 'ST' appears in Requirements/Limits (examples include FANAPT titration packs and SAVELLA). Providers should follow the plan's ST requirements for these agents.

    Formulary Background and Scope

    This formulary includes both brand‑name and generic medications and notes that pharmacists will generally dispense generic equivalents when available. The document describes utilization management tools used by the plan — principally PA (prior authorization), QL (quantity limits) and ST (step therapy) — and indicates that many specialty drugs require specialty pharmacy handling (SP) or have limited access/site‑of‑care designations (LA). Home delivery is available and may be an option for ongoing chronic therapy.

    Policy Dates & Revision Notes

    2026-04-01policy_effectiveLatest

    Formulary updated and effective on April 1, 2026.

    2026-04-01last_review

    Policy last reviewed on April 1, 2026.

    2026-04-01next_review

    Next scheduled review date set for April 1, 2026.